Amphastar Pharmaceuticals Inc (AMPH)

16.03
0.53 3.20
NASDAQ : Health Care
Prev Close 16.56
Open 16.48
Day Low/High 16.00 / 16.48
52 Wk Low/High 10.50 / 17.80
Volume 241.28K
Avg Volume 402.40K
Exchange NASDAQ
Shares Outstanding 46.02M
Market Cap 759.85M
EPS -0.10
P/E Ratio 35.89
Div & Yield N.A. (N.A)

Latest News

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Amphastar Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Amphastar Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm

Khang & Khang LLP (the "Firm") announces that it is investigating claims against Amphastar Pharmaceuticals, Inc.

Interesting AMPH Put And Call Options For February 2017

Interesting AMPH Put And Call Options For February 2017

Investors in Amphastar Pharmaceuticals Inc saw new options begin trading this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AMPH options chain for the new February 2017 contracts and identified one put and one call contract of particular interest.

Amphastar Pharmaceuticals Becomes Oversold (AMPH)

Amphastar Pharmaceuticals Becomes Oversold (AMPH)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of November 18th Options Trading For Amphastar Pharmaceuticals (AMPH)

First Week of November 18th Options Trading For Amphastar Pharmaceuticals (AMPH)

Investors in Amphastar Pharmaceuticals Inc saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AMPH options chain for the new November 18th contracts and identified one put and one call contract of particular interest.

Amphastar Pharmaceuticals Reaches Analyst Target Price

Amphastar Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Amphastar Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $21.00, changing hands for $21.26/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Commit To Purchase Amphastar Pharmaceuticals At $17.50, Earn 23.3% Annualized Using Options

Commit To Purchase Amphastar Pharmaceuticals At $17.50, Earn 23.3% Annualized Using Options

Investors considering a purchase of Amphastar Pharmaceuticals Inc stock, but tentative about paying the going market price of $18.81/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $17.50 strike, which has a bid at the time of this writing of $1.35.

AMPH Crosses Above Average Analyst Target

AMPH Crosses Above Average Analyst Target

In recent trading, shares of Amphastar Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $18.00, changing hands for $18.17/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Shark Bites: Join the Momentum Parade

The benefits of following the big movers.

Amphastar Pharmaceuticals Reports Financial Results For The Three Months Ended June 30, 2016

Amphastar Pharmaceuticals Reports Financial Results For The Three Months Ended June 30, 2016

Reports Net Revenues of $68.0 Million for the Three Months Ended June 30, 2016

Insider Trading Alert - GES, AMPH And ALOG Traded By Insiders

Insider Trading Alert - GES, AMPH And ALOG Traded By Insiders

Stocks with insider trader activity include GES, AMPH and ALOG

Pricing Stress may Weigh on Generic Drugmakers Ahead of Q2 Earnings

Pricing Stress may Weigh on Generic Drugmakers Ahead of Q2 Earnings

Endo Pharmaceuticals is most under pressure, analysts say.

Trade-Ideas: Amphastar Pharmaceuticals (AMPH) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Amphastar Pharmaceuticals (AMPH) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Amphastar Pharmaceuticals (AMPH) as a weak on high relative volume candidate

Insider Trading Alert - AMPH, IPAS And SNCR Traded By Insiders

Insider Trading Alert - AMPH, IPAS And SNCR Traded By Insiders

Stocks with insider trader activity include AMPH, IPAS and SNCR

Amphastar Pharmaceuticals Reports Financial Results For The First Quarter Ended March 31, 2016

Amphastar Pharmaceuticals Reports Financial Results For The First Quarter Ended March 31, 2016

Reports Net Revenues of $59.4 Million for the First Quarter Ended March 31, 2016

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMPH, CNS, FTD, HCAP, HQCL, LOCK, NE, OSUR, PB, TUP Downgrades: BCRH Initiations: None Read on to get TheStreet Quant Ratings' detailed report: